课题基金 / 基金详情

Development of a novel mesothelin CAR-T immunotherapy and pharmacologic combinations for triple negative breast cancer

Development of a novel mesothelin CAR-T immunotherapy and pharmacologic combinations for triple negative breast cancer
开发新型间皮素 CAR-T 免疫疗法和药物组合治疗三阴性乳腺癌
批准号:
390724
负责人:
Hirano Naoto
金额:
$92.79万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2018
资助国家:
加拿大
项目状态:
已结题
起止时间:
2018-09-01 至 2023-09-01

项目摘要

项目成果

Hirano Naoto的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Triple negative breast cancer is an aggressive form of the disease, for which current treatment options are limited, and survival outcomes are poor. More effective options are needed, and successful development of the next generation of treatments demands
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of bi-specific T cell engagers (BiTEs) for the treatment of acute myeloid leukemia (AML)
  • 批准号:
    478239
  • 项目类别:
    Operating Grants
  • 资助金额:
    $74.12万
  • 财政年份:
    2023
  • 负责人:
    Hirano Naoto
  • 依托单位:
Development of TCR-engineered T cells against novel NY-ESO-1 epitopes for the treatment of triple negative breast cancer
  • 批准号:
    435378
  • 项目类别:
    Operating Grants
  • 资助金额:
    $104.77万
  • 财政年份:
    2020
  • 负责人:
    Hirano Naoto
  • 依托单位:
Novel CAR-T cell therapy targeting a Wilms Tumor 1 peptide presented by multiple HLA-DP alleles
  • 批准号:
    342733
  • 项目类别:
    Operating Grants
  • 资助金额:
    $50.12万
  • 财政年份:
    2016
  • 负责人:
    Hirano Naoto
  • 依托单位:
海外基金